Mono Pharmacare

Why is Mono Pharmacare Ltd falling/rising?

As of 01-Sep, Mono Pharmacare Ltd's stock price is at 8.55, reflecting a 5.0% decline. The stock has significantly underperformed the market and its sector, with notable losses over various periods, indicating a bearish trend despite increased investor participation.

As of 01-Sep, Mono Pharmacare Ltd's stock price is falling, currently at 8.55, which reflects a decrease of 0.45 or 5.0%. This decline is evident in the stock's performance over various periods, with a 1-week drop of 1.16%, a 1-month decrease of 14.07%, and a year-to-date decline of 43.75%. In comparison, the benchmark Sensex has also experienced losses, but at a significantly lower rate, indicating that Mono Pharmacare Ltd is underperforming relative to the market.<BR><BR>Today's performance shows that the stock has underperformed its sector by 4.4%. Although the stock is trading higher than its 20-day moving average, it is below the 5-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. Additionally, while there has been a rise in investor participation, with delivery volume increasing by 66.67% against the 5-day average, this has not translated into a positive price movement. Overall, the combination of significant declines in stock performance over multiple time frames and underperformance against benchmarks contributes to the current falling price of Mono Pharmacare Ltd.

Which are the latest news on Mono Pharmacare?

What does Mono Pharmacare do?

Mono Pharmacare Ltd markets and distributes pharmaceutical products and was converted from a partnership to a public limited company in October 2022. It has a market cap of INR 16 Cr, with a P/E ratio of 45.00 and no recent revenue or profit data available.

Overview:<BR>Mono Pharmacare Ltd is engaged in the marketing and distribution of pharmaceutical products within the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History:<BR>Mono Pharmacare Limited was originally formed as a Partnership Firm named "M/s. Mono Chemist" on May 06, 1994. It was converted into a Public Limited company on October 17, 2022, as per the Certificate of Incorporation issued by the Registrar of Companies, Ahmedabad. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 16 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 45.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 1.76<BR>Return on Equity: 1.11%<BR>Price to Book: 0.50<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the peers of the Mono Pharmacare?

Mono Pharmacare's peers include Saroja Pharma In, Ortin Global, Zenith Health, Desh Rakshak, Bacil Pharma, Dipna Pharmachem, Colinz Labs, Starsource Multi, and Shree Ganesh Bio. Key insights show varying management risks and growth rates, with Ortin Global leading in 1-year returns at 14.18%.

Peers: The peers of Mono Pharmacare are Saroja Pharma In, Ortin Global, Zenith Health, Desh Rakshak, Bacil Pharma, Dipna Pharmachem, Colinz Labs, Starsource Multi, and Shree Ganesh Bio.<BR><BR>Quality Snapshot: Excellent growth is observed at Dipna Pharmachem, while Average management risk is found at Saroja Pharma In, and Below Average management risk is noted at Mono Pharmacare, Ortin Global, Zenith Health, Desh Rakshak, Colinz Labs, and Shree Ganesh Bio, with Bacil Pharma and Starsource Multi not qualifying. Below Average growth is seen at Mono Pharmacare, Saroja Pharma In, Ortin Global, Zenith Health, Desh Rakshak, Colinz Labs, and Shree Ganesh Bio, while Bacil Pharma and Starsource Multi do not qualify. Good capital structure is noted at Zenith Health, Colinz Labs, and Shree Ganesh Bio, while Below Average capital structure is present at Mono Pharmacare, Saroja Pharma In, Ortin Global, Desh Rakshak, Dipna Pharmachem, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Ortin Global at 14.18%, while Bacil Pharma, Starsource Multi, Zenith Health, Desh Rakshak, and others have a 1-year return of 0.00%, indicating that Mono Pharmacare's 1-year return is not available for comparison. Additionally, Ortin Global has a negative six-month return of -6.54%.

How big is Mono Pharmacare?

As of 14th August, Mono Pharmacare Ltd has a market capitalization of 14.00 Cr, classifying it as a Micro Cap company, with no valid financial data available for Net Sales or Net Profit for the latest four quarters. The balance sheet as of March 2025 shows Shareholder's Funds of 31.20 Cr and Total Assets of 110.01 Cr.

As of 14th August, <BR><BR>Market Cap: Mono Pharmacare Ltd has a market capitalization of 14.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 31.20 Cr and Total Assets totaling 110.01 Cr.

How has been the historical performance of Mono Pharmacare?

Mono Pharmacare exhibited strong financial growth from March 2024 to March 2025, with net sales rising from 122.34 Cr to 168.34 Cr and profit after tax increasing from 2.46 Cr to 3.11 Cr, despite ongoing negative cash flow from operating activities. Total liabilities and debt also increased, but current assets improved, indicating better liquidity.

Answer:<BR>The historical performance of Mono Pharmacare shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Mono Pharmacare's net sales increased significantly from 122.34 Cr in March 2024 to 168.34 Cr in March 2025, reflecting a robust growth in total operating income, which also rose to 168.34 Cr from 122.34 Cr. The total expenditure, excluding depreciation, rose to 160.71 Cr from 116.01 Cr, primarily driven by higher purchases of finished goods and other expenses. Operating profit, excluding other income, improved to 7.63 Cr from 6.33 Cr, leading to an overall operating profit of 8.61 Cr compared to 6.43 Cr the previous year. Profit before tax increased to 4.46 Cr from 3.23 Cr, and profit after tax rose to 3.11 Cr from 2.46 Cr. The consolidated net profit also saw an increase to 3.09 Cr from 2.44 Cr, with earnings per share growing to 1.75 from 1.38. On the balance sheet, total liabilities increased to 110.01 Cr from 81.10 Cr, with total debt rising to 53.56 Cr from 41.44 Cr. Current assets also grew significantly to 108.99 Cr from 80.16 Cr, indicating improved liquidity. However, cash flow from operating activities remained negative at -4.00 Cr, though it was an improvement from -8.00 Cr the previous year. Overall, Mono Pharmacare demonstrated strong revenue growth and profitability improvements, despite challenges in cash flow management.

Is Mono Pharmacare overvalued or undervalued?

As of November 10, 2025, Mono Pharmacare is considered overvalued with a valuation grade of expensive, reflected by its PE Ratio of 11.72 and underperformance of 43.84% compared to the Sensex's 5.91% gain, especially when compared to peers like Sun Pharma and Cipla.

As of 10 November 2025, the valuation grade for Mono Pharmacare has moved from very expensive to expensive. The company is currently considered overvalued based on its financial ratios. Key ratios include a PE Ratio of 11.72, an EV to EBITDA of 11.68, and a PEG Ratio of 0.44, which indicates potential growth at a reasonable price compared to its earnings.<BR><BR>When comparing Mono Pharmacare to its peers, Sun Pharma has a significantly higher PE Ratio of 35.15, while Cipla, which is rated attractive, has a PE Ratio of 22.45. This suggests that Mono Pharmacare's valuation is not justified when looking at the broader industry context, especially given its recent stock performance, which has underperformed the Sensex over the past year, with a decline of 43.84% compared to the Sensex's gain of 5.91%.

Who are the top shareholders of the Mono Pharmacare?

The top shareholder of Mono Pharmacare is Lakhatariya Panilam, holding 45.43% of the shares. The highest public shareholder is Harshad Rasiklal Sheth at 3.68%, while individual investors collectively own 35.6%.

The top shareholders of Mono Pharmacare include the promoters, with Lakhatariya Panilam holding the largest share at 45.43%. There are no pledged promoter holdings, and mutual funds and foreign institutional investors do not hold any shares in the company. The highest public shareholder is Harshad Rasiklal Sheth, who owns 3.68%. Additionally, individual investors collectively hold 35.6% of the shares.

What is the technical trend for Mono Pharmacare?

As of May 19, 2025, Mono Pharmacare's technical trend is mildly bearish, indicated by daily moving averages and monthly Bollinger Bands, despite some conflicting signals from weekly MACD and KST.

As of 19 May 2025, the technical trend for Mono Pharmacare has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, suggesting some conflicting signals. The Bollinger Bands show a bearish trend on the monthly timeframe, further supporting the bearish outlook. The stock has experienced a significant decline year-to-date and over the past year, underperforming compared to the Sensex. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly Bollinger Bands.

When is the next results date for Mono Pharmacare?

No Upcoming Board Meetings

Has Mono Pharmacare declared dividend?

No Dividend History Available